Literature DB >> 24217444

The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Dylan P Kennedy1, Fiona M McRobb, Susan A Leonhardt, Michael Purdy, Heidi Figler, Melissa A Marshall, Mahendra Chordia, Robert Figler, Joel Linden, Ruben Abagyan, Mark Yeager.   

Abstract

Allosteric enhancers of the adenosine A1 receptor amplify signaling by orthosteric agonists. Allosteric enhancers are appealing drug candidates because their activity requires that the orthosteric site be occupied by an agonist, thereby conferring specificity to stressed or injured tissues that produce adenosine. To explore the mechanism of allosteric enhancer activity, we examined their action on several A1 receptor constructs, including (1) species variants, (2) species chimeras, (3) alanine scanning mutants, and (4) site-specific mutants. These findings were combined with homology modeling of the A1 receptor and in silico screening of an allosteric enhancer library. The binding modes of known docked allosteric enhancers correlated with the known structure-activity relationship, suggesting that these allosteric enhancers bind to a pocket formed by the second extracellular loop, flanked by residues S150 and M162. We propose a model in which this vestibule controls the entry and efflux of agonists from the orthosteric site and agonist binding elicits a conformational change that enables allosteric enhancer binding. This model provides a mechanism for the observations that allosteric enhancers slow the dissociation of orthosteric agonists but not antagonists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217444      PMCID: PMC3913357          DOI: 10.1124/mol.113.088682

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  53 in total

Review 1.  G protein-coupled receptor allosterism and complexing.

Authors:  Arthur Christopoulos; Terry Kenakin
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

2.  Protective effects of cyclohexyladenosine following cerebral ischemia in the gerbil hippocampus.

Authors:  J L Daval; D K von Lubitz; J Deckert; P J Marangos
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

Review 3.  Regulation of G protein-coupled receptors by allosteric ligands.

Authors:  J Robert Lane; Alaa Abdul-Ridha; Meritxell Canals
Journal:  ACS Chem Neurosci       Date:  2013-02-21       Impact factor: 4.418

4.  Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain.

Authors:  Xinhui Li; Dawn Conklin; Weiya Ma; Xiaoying Zhu; James C Eisenach
Journal:  Pain       Date:  2002-05       Impact factor: 6.961

5.  Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor.

Authors:  P G Baraldi; A N Zaid; I Lampronti; F Fruttarolo; M G Pavani; M A Tabrizi; J C Shryock; E Leung; R Romagnoli
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

6.  Protective effect of cyclohexyladenosine on adenosine A1-receptors, guanine nucleotide and forskolin binding sites following transient brain ischemia: a quantitative autoradiographic study.

Authors:  J L Daval; D K Von Lubitz; J Deckert; D J Redmond; P J Marangos
Journal:  Brain Res       Date:  1989-07-10       Impact factor: 3.252

7.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes.

Authors:  R F Bruns; J H Fergus
Journal:  Mol Pharmacol       Date:  1990-12       Impact factor: 4.436

8.  Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism.

Authors:  Xinhui Li; Dawn Conklin; Hui-Lin Pan; James C Eisenach
Journal:  J Pharmacol Exp Ther       Date:  2003-02-20       Impact factor: 4.030

9.  Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors.

Authors:  Uta Voigtländer; Kirstin Jöhren; Marion Mohr; Alexandra Raasch; Christian Tränkle; Stefan Buller; John Ellis; Hans-Dieter Höltje; Klaus Mohr
Journal:  Mol Pharmacol       Date:  2003-07       Impact factor: 4.436

10.  Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding.

Authors:  Heidi Figler; Ray A Olsson; Joel Linden
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

View more
  5 in total

Review 1.  New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.

Authors:  Elizabeth A Vecchio; Jo-Anne Baltos; Anh T N Nguyen; Arthur Christopoulos; Paul J White; Lauren T May
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

2.  Prediction of consensus binding mode geometries for related chemical series of positive allosteric modulators of adenosine and muscarinic acetylcholine receptors.

Authors:  Leon A Sakkal; Kyle Z Rajkowski; Roger S Armen
Journal:  J Comput Chem       Date:  2017-01-28       Impact factor: 3.376

3.  Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.

Authors:  Alaa Abdul-Ridha; J Robert Lane; Shailesh N Mistry; Laura López; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos; Meritxell Canals
Journal:  J Biol Chem       Date:  2014-10-17       Impact factor: 5.157

4.  Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor.

Authors:  Steven M Moss; P Suresh Jayasekara; Silvia Paoletta; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2014-07-11       Impact factor: 4.345

5.  Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor.

Authors:  Giuseppe Deganutti; Kerry Barkan; Barbara Preti; Michele Leuenberger; Mark Wall; Bruno G Frenguelli; Martin Lochner; Graham Ladds; Christopher A Reynolds
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.